Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Kne...
January 07 2021 - 7:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that UnitedHealthcare has expanded its medical policy for
MACI® (autologous cultured chondrocytes on porcine collagen
membrane) to include coverage for patients with symptomatic
full-thickness cartilage defects in the patella and multiple
cartilage defects in the knee. UnitedHealthcare is the largest
commercial payer in the United States, covering more than 26
million lives, and more patients treated with MACI are covered by
UnitedHealthcare than any other plan in the United States. The
revised policy is effective February 1, 2021.
“We are very pleased that United Healthcare has expanded MACI
coverage to include patients with patella and multiple cartilage
defects in the knee, which is consistent with the MACI label and
current clinical practice,” said Nick Colangelo, President and CEO
of Vericel. “Since its launch, MACI has become a preferred
treatment option, particularly for patients with cartilage defects
on the patella, and this updated policy will increase patient
access and support continued MACI growth in the years ahead.”
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2020 Vericel
Corporation. All rights reserved.
Forward Looking StatementsThis press release
contains forward-looking statements. Forward-looking statements are
subject to risks and uncertainties such as those described
in Vericel’s periodic reports on file with the Securities
and Exchange Commission. Actual results may differ materially from
anticipated results.
Investor Contacts:Chad RubinSolebury
Troutcrubin@troutgroup.com+1 646-378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024